20 years of revenue, earnings, cash-flow and balance-sheet history from public filings.
Maravai Lifesciences Holdings Inc (MRVI) operates in the BIOTECHNOLOGY industry and is headquartered in San Diego, United States with about 415 employees. Its market capitalization is roughly $3 billion. In the fiscal year ended 2025-12-31, MRVI reported $186M in revenue and ($131M) in net income.
Maravai LifeSciences Holdings, Inc., a life sciences company, provides products that enable the development of drug therapies, vaccines, drug therapies, cell and gene therapies, and diagnostics North America, Europe, the Middle East, Africa, the Asia Pacific, and Latin and Central America.
Interactive charts & full statements → Open the MRVI valuation workbench →
| Income statement | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $209M | $186M | $259M | $289M | $883M | $799M | $284M | $143M | $124M |
| Gross Profit | $72M | $33M | $108M | $140M | $714M | $659M | $204M | $76M | $63M |
| Gross Margin % | 34.6% | 18.0% | 41.8% | 48.5% | 80.9% | 82.4% | 72.0% | 53.3% | 50.9% |
| Operating Income (EBIT) | $96M | ($7M) | ($236M) | ($32M) | $574M | $555M | $120M | $24M | $16M |
| Operating Margin % | 46.0% | -3.6% | -90.9% | -10.9% | 65.0% | 69.4% | 42.2% | 16.8% | 13.3% |
| Net Income | ($77M) | ($131M) | ($145M) | ($119M) | $220M | $182M | $77M | ($8M) | ($18M) |
| Net Margin % | -37.1% | -70.4% | -55.9% | -41.2% | 24.9% | 22.8% | 27.1% | -5.9% | -14.3% |
| EBITDA | ($57M) | ($147M) | ($157M) | $712M | $610M | $586M | $138M | $48M | $33M |
| Earnings Per Share (EPS) | $-0.53 | $-0.90 | $-1.05 | $-0.90 | $1.67 | $1.49 | $0.80 | $-0.09 | $-0.20 |
| Shares Outstanding (M) | 148M | 145M | 138M | 132M | 132M | 122M | 97M | 97M | 89M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly income statement | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Total Revenue | $51M | $66M | $50M | $42M | $47M | $47M | $56M | $65M |
| Gross Profit | $21M | $34M | $12M | $6M | $8M | $8M | $19M | $28M |
| Gross Margin % | 40.1% | 51.2% | 24.6% | 13.6% | 16.4% | 16.5% | 33.6% | 43.5% |
| Operating Income (EBIT) | ($15M) | $2M | ($7M) | $115M | ($66M) | ($49M) | ($38M) | ($169M) |
| Operating Margin % | -29.3% | 3.8% | -13.5% | 277.3% | -139.8% | -104.9% | -67.6% | -259.4% |
| Net Income | ($12M) | ($4M) | ($36M) | ($26M) | ($40M) | ($30M) | ($26M) | ($99M) |
| Net Margin % | -24.1% | -5.7% | -71.5% | -61.4% | -83.5% | -63.9% | -46.4% | -151.9% |
| EBITDA | ($5M) | $12M | ($42M) | ($22M) | ($52M) | ($31M) | ($21M) | ($148M) |
| Earnings Per Share (EPS) | $-0.08 | $-0.03 | $-0.25 | $-0.18 | $-0.27 | $-0.21 | $-0.19 | $-0.70 |
| Shares Outstanding (M) | 148M | 146M | 145M | 145M | 144M | 143M | 140M | 142M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Cash flow | TTM → 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | ($25M) | ($58M) | $7M | $126M | $536M | $369M | $152M | $24M | $0M |
| Capital Expenditures (CapEx) | $10M | $13M | $30M | $66M | $17M | $15M | $25M | $17M | $4M |
| Free Cash Flow (FCF) | ($35M) | ($71M) | ($22M) | $61M | $519M | $354M | $127M | $7M | ($4M) |
| FCF Margin % | -16.8% | -38.1% | -8.6% | 21.0% | 58.8% | 44.3% | 44.6% | 4.9% | -3.1% |
| Dividends Paid | — | — | — | — | — | $153M | $609M | $97M | $52M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Quarterly cash flow | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 |
|---|---|---|---|---|---|---|---|---|
| Cash from Operations (CFO) | $4M | $9M | ($23M) | ($15M) | ($10M) | ($9M) | ($15M) | $13M |
| Capital Expenditures (CapEx) | $0M | $4M | $2M | $3M | $3M | $5M | $6M | $10M |
| Free Cash Flow (FCF) | $4M | $4M | ($25M) | ($18M) | ($13M) | ($15M) | ($20M) | $4M |
| FCF Margin % | 7.0% | 6.4% | -49.9% | -43.4% | -27.7% | -31.2% | -36.3% | 5.4% |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
| Balance sheet | 2026-06-30 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|---|
| Total Assets | $604M | $771M | $1.0B | $1.5B | $2.3B | $1.9B | $1.3B | $578M | $540M |
| Cash & Cash Equivalents | $70M | $217M | $322M | $575M | $632M | $551M | $236M | $25M | $22M |
| Total Liabilities | $248M | $398M | $431M | $698M | $1.4B | $1.4B | $1.1B | $433M | $392M |
| Total Debt (Short + Long-Term) | $147M | $292M | $304M | $532M | $534M | $534M | $535M | $337M | $338M |
| Total Shareholders' Equity | $205M | $212M | $325M | $417M | $545M | $315M | $89M | $141M | $144M |
USD; $M / $B as marked. Newest period first. Source: public company filings (via Yahoo Finance aggregation).
Quarterly statements, profitability ratios, price history, insider activity and institutional holders are in the interactive MRVI viewer.
About TickerBase · Data methodology & sources · Privacy · Terms